KCTBASE

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis

The Korean Journal of Internal Medicine 2014년 29권 2호 p.176 ~ p.182

이지혜(Lee Ji-Hye) - Soonchunhyang University College of Medicine Department of Pathology
오미혜(Oh Mee-Hye) - Soonchunhyang University College of Medicine Department of Pathology
박재석(Park Jae-Seok) - Soonchunhyang University College of Medicine Department of Internal Medicine
(Na Gyoung-Jae) - Soonchunhyang University College of Medicine Department of Internal Medicine
길혜욱(Gil Hye-Wook) - Soonchunhyang University College of Medicine Department of Internal Medicine
양종오(Yang Jong-Oh) - Soonchunhyang University College of Medicine Department of Internal Medicine
이은영(Lee Eun-Young) - Soonchunhyang University College of Medicine Department of Internal Medicine
홍세용(Hong Sae-Yong) - Soonchunhyang University College of Medicine Department of Internal Medicine

Abstract

Background/Aims: The purpose of this study was to investigate the expression of urokinase-type plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor (PAI)-1 on podocytes in immunoglobulin A (IgA) glomerulonephritis (GN).

Methods: Renal biopsy specimens from 52 IgA GN patients were deparaffinized and subjected to immunohistochemical staining for uPA, PAI-1, and uPAR. The biopsies were classified into three groups according to the expression of uPA and uPAR on podocytes: uPA, uPAR, and a negative group. The prevalences of the variables of the Oxford classification for IgA GN were compared among the groups.

Results: On podocytes, uPA was positive in 11 cases and uPAR was positive in 38 cases; by contrast, PAI-1 was negative in all cases. Expression of both uPA and uPAR on podocytes was less frequently accompanied by tubulointerstitial fibrosis.

Conclusions: Our results suggest a possible protective effect of podocyte uPA/ uPAR expression against interstitial fibrosis.